Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases: The BEST Study.

*Department of Accounting and Finance at Kingston University †Department of Statistical Science, University College London, London, UK ‡Biostatistics Unit, Department of Statistics, University of Milano-Bicocca, Milan §CEIS Sanità (CHEM-Centre for Health Economics and Management), Faculty of Economics, University of Tor Vergata, Rome ∥Department of Gynecology and Obstetrics, S. Orsola-Malpighi Hospital, University of Bologna, Bologna ¶Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome #Laboratory of Cutaneous Pathophysiology, San Gallicano Dermatological Institute (IRCCS), Rome, Italy **Centre for Health Economics Alcuin A Block, University of York, Heslington, UK ††Stockholm School of Economics, Stockholm, Sweden ‡‡Socioeconomic Institute, University of Zurich, Zurich, Switzerland.
Medical care (Impact Factor: 2.94). 08/2012; 50(12). DOI: 10.1097/MLR.0b013e318269e06d
Source: PubMed

ABSTRACT BACKGROUND:: The development of human papillomavirus (HPV)-related diseases is not understood perfectly and uncertainties associated with commonly utilized probabilistic models must be considered. The study assessed the cost-effectiveness of a quadrivalent-based multicohort HPV vaccination strategy within a Bayesian framework. METHODS:: A full Bayesian multicohort Markov model was used, in which all unknown quantities were associated with suitable probability distributions reflecting the state of currently available knowledge. These distributions were informed by observed data or expert opinion. The model cycle lasted 1 year, whereas the follow-up time horizon was 90 years. Precancerous cervical lesions, cervical cancers, and anogenital warts were considered as outcomes. RESULTS:: The base case scenario (2 cohorts of girls aged 12 and 15 y) and other multicohort vaccination strategies (additional cohorts aged 18 and 25 y) were cost-effective, with a discounted cost per quality-adjusted life-year gained that corresponded to &OV0556;12,013, &OV0556;13,232, and &OV0556;15,890 for vaccination programs based on 2, 3, and 4 cohorts, respectively. With multicohort vaccination strategies, the reduction in the number of HPV-related events occurred earlier (range, 3.8-6.4 y) when compared with a single cohort. The analysis of the expected value of information showed that the results of the model were subject to limited uncertainty (cost per patient=&OV0556;12.6). CONCLUSIONS:: This methodological approach is designed to incorporate the uncertainty associated with HPV vaccination. Modeling the cost-effectiveness of a multicohort vaccination program with Bayesian statistics confirmed the value for money of quadrivalent-based HPV vaccination. The expected value of information gave the most appropriate and feasible representation of the true value of this program.

Download full-text


Available from: Andrea Marcellusi, Aug 31, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Public payment is key to market access for new therapeutics including cancer vaccines and cancer immunotherapeutics. However, the methodology for economic evaluation aimed at informing decisions about pricing and reimbursement is different for cancer vaccines, such as HPV for preventing the occurrence or incidence of cancer, and immunotherapeutics for treatment of patients with manifest cancer. Vaccination against HPV is a traditional public health intervention, where the role of economic evaluation is to inform decisions about optimal vaccination strategies. The decision is about funding for a vaccination program, aimed at vaccinating a defined population at risk, either at a national or regional level. The methodology of economic evaluation is based on statistical modeling of number of cases prevented over a long time period, and the costs and health outcome related to this, for different vaccination strategies
    Human Vaccines & Immunotherapeutics 08/2012; 8(9). DOI:10.4161/hv.21921 · 3.64 Impact Factor
  • Source
    Medical care 01/2013; 51(4). DOI:10.1097/MLR.0b013e3182836de8 · 2.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A large number of economic evaluations have already confirmed the cost-effectiveness of different human papillomavirus (HPV) vaccination strategies. Standard analyses might not capture the full economic value of novel vaccination programs because the cost-effectiveness paradigm fails to take into account the value of active management. Management decisions can be seen as real options, a term used to refer to the application of option pricing theory to the valuation of investments in nonfinancial assets in which much of the value is attributable to flexibility and learning over time.
    Clinical Therapeutics 06/2013; 35(7). DOI:10.1016/j.clinthera.2013.05.003 · 2.59 Impact Factor
Show more